Cystic Fibrosis Foundation Therapeutics Extends Drug Development Collaboration with Proteostasis Therapeutics

Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT), an affiliate of the Cystic Fibrosis Foundation, announced it will extend funding for continued collaboration with Proteostasis Therapeutics, Inc., for the development of new therapies to treat the most common CF mutation, Delta F508.

| 2 min read

Proteostasis will continue to focus its research and development on small molecules that correct defective CFTR protein in the cell and allow it to function properly. 

In the Delta F508 mutation, the defective protein CFTR does not move to its proper place at the cell surface, impeding the flow of fluids into the airways. Nearly 90 percent of people with CF have at least one copy of the Delta F508 mutation.

In addition to this collaboration, CFFT is investing in a robust pipeline of potential therapies that target CF from every angle, including research collaborations with Pfizer, Genzyme and Vertex to accelerate the discovery and development of new drugs.

CFFT's and the Foundation's goal is to find effective therapies and a cure for 100 percent of people with the disease.

Proteostasis Therapeutics develops disease-modifying therapeutics for orphan and neurodegenerative diseases.

Additional Resources

Share this article
Topics
About the CF Foundation | CFTR Modulators | Genetic Therapies
Recent news
CF Foundation Reflects on Progress Toward Equity, Racial Justice, Diversity, and Inclusion
News | 4 min read
CF Foundation Invests Up to $3.5M in Gensaic for Novel Gene Delivery Method
News | 2 min read
CF Foundation Urges Vertex Pharmaceuticals to Reverse Consequential Decision on Copay Assistance
News | 3 min read
Stay up to date with The Foundation

Sign up for our newsletter to get all of the latest news from The Foundation right in your inbox.

Subscribe